Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer
A phase 2/3 trial of PM8002, Pembrolizumab, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by BioNTech SE, now recruiting.
Overview
Safety, Efficacy, and Pharmacokinetics of BNT327 in Combination With Chemotherapy and Other Investigational Agents for Lung Cancer is a phase 2/3 interventional study registered as NCT06712316 by BioNTech SE, with 1580 participants planned, started 2025-01-07 and due to reach its primary completion in 2029-01. Interventions recorded: Pumitamig, Pembrolizumab, Carboplatin, Pemetrexed, Paclitaxel. Conditions listed: Non-small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Similar pages
not linked directly; found by shared links- TrialA Global Study of Volrustomig (MEDI5752) Plus Chemotherapy Versus Pembrolizumab Plus Chemotherapy for Participants With Metastatic Non-small Cell Lung
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialA Study To Assess the Safety, Tolerability, and Efficacy of Imzokitug in Combination With Pumitamig and Platinum-Doublet Chemotherapy (PDCT) Versus Pu
Shares PM8002, Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin.
- TrialStudy of Pembrolizumab (MK-3475) Subcutaneous (SC) Versus Pembrolizumab Intravenous (IV) Administered With Platinum Doublet Chemotherapy in Participan
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialPM8002 in Combination With Paclitaxel Compared With Chemotherapy as Second-line Treatment in Small Cell Lung Cancer
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Clinical Trial to Test if an Investigational Combination Therapy With BNT326 and BNT327 is Safe and Potentially Beneficial for People With Advanced
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.
- TrialA Study of Pembrolizumab With or Without Chemotherapy in Combination With Additional Treatments for Advanced Non-Small Cell Lung Cancer (NSCLC) (MK-34
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Pembrolizumab.
- TrialIPH5201 and Durvalumab in Patients With Resectable Non-Small Cell Lung Cancer (MATISSE)
Shares Pemetrexed, Paclitaxel / nab-paclitaxel, Carboplatin, Small-cell lung cancer.
- TrialSafety and Preliminary Efficacy of Pumitamig (BNT327), an Investigational Therapy for Patients With Non-small Cell Lung Cancer in Combination With Che
Shares PM8002, BioNTech, Small-cell lung cancer, Non-small-cell lung cancer.